ProShare Advisors
DSGN icon

ProShare Advisors’s Design Therapeutics DSGN Stock Holding History

ProShare Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,525
Closed -$71.1K – 2141
2024
Q4 		$71.1K Buy
+11,525
New +$66.7K ﹤0.01% 2130
2022
Q2 		– Sell
-10,755
Closed -$174K – 1884
2022
Q1 		$174K Sell
10,755
-2,841
-21% -$43.5K ﹤0.01% 1917
2021
Q4 		$291K Buy
+13,596
New +$233K ﹤0.01% 1807

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ProShare Advisors's DSGN Position: Q1 2025 in Review

ProShare Advisors sold out of Design Therapeutics (DSGN) in Q1 2025, closing a stake of 11,525 shares — an estimated $71.1K sold.

ProShare Advisors first reported a position in DSGN in Q4 2021 and held it in 3 quarters. The position peaked at $291K in Q4 2021. 98 funds tracked by Wall St. Rank hold DSGN as of Q1 2025.

  • ProShare Advisors reported no remaining Design Therapeutics position as of Q1 2025 after selling out during the quarter.
  • ProShare Advisors sold 11,525 Design Therapeutics shares in Q1 2025, an estimated $71.1K.
  • ProShare Advisors first reported a position in Design Therapeutics in Q4 2021 and held it in 3 quarters.
  • ProShare Advisors's Design Therapeutics position peaked at $291K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.